Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Core Insights - Armata Pharmaceuticals has appointed David House as Senior Vice President of Finance, effective August 16, 2024, to strengthen its financial leadership as it advances its bacteriophage therapeutic programs [1][2]. Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics aimed at treating antibiotic-resistant and difficult-to-treat bacterial infections [4]. - The company is advancing a pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [4]. Leadership Appointment - David House brings extensive experience in accounting and finance from previous roles at ZO Skin Health, Peregrine Pharmaceuticals, and Avid Bioservices, where he managed financial operations and played key roles in acquisitions and financial reporting [2][3]. - His appointment is expected to enhance Armata's ability to achieve long-term success and prepare for pivotal studies of its therapeutic programs [2].